NYSE:PBHPharmaceuticals
Why Prestige Consumer Healthcare (PBH) Is Down 5.8% After Heightened Regulatory Scrutiny On Its OTC Portfolio
In early April 2026, Prestige Consumer Healthcare faced pressure after regulatory scrutiny, including FTC concerns over industry consolidation and a federal healthcare fraud crackdown, weighed on sentiment around its over-the-counter product portfolio.
Beyond the immediate regulatory overhang, the episode highlights how sector-wide oversight can quickly reshape market perceptions of risk around even established healthcare brands.
Against this backdrop of intensified regulatory attention,...